Ritanserin, a serotonin-s2 receptor antagonist, does not prevent 5-hydroxytryptophan-induced β-ep, β-lph and cortisol secretion

F. Facchinetti, E. Martignoni, G. Nappi, S. Marini, F. Petraglia, G. Sandrini, A. R. Genazzani

Research output: Contribution to journalArticlepeer-review

Abstract

Ritanserin, a new serotonin antagonist selective upon S2 receptor subclass is available. Thus, in order to better define the positive control of serotoninergic pathway on proopiomelanocortin (POMC)-related peptide release, a group of 7 healthy male volunteers has been submitted to a 5-hydroxytryptophane (5-OH-TP) test (200 mg p.o.) before and after 4days Ritanserin pretreatment. Plasma β-endorphin (β-EP), p-lipotropin (β-LPH) and cortisol levels were measured hourly for 4 h after each 5-OH-TP loading. Hormonal levels were measured by specific RIAs on extracted (cortisol) and chromatographed (β-EP and β-LPH) plasma samples. Basal plasma concentrations of the three hormones were unchanged by Ritanserin pretreatment. Similarly, the integrated areas of β-LPH, β-EP and cortisol release in response to 5-OH-TP remained unaffected by the receptor blockade. These data confirm that serotonin-acting drugs are able to stimulate POMC-related peptide release and indicatethat such interaction is not mediated through S2 receptor subclass.

Original languageEnglish
Pages (from-to)42-46
Number of pages5
JournalHormone Research in Paediatrics
Volume27
Issue number1
DOIs
Publication statusPublished - 1987

Keywords

  • 5-Hydroxytryptophan
  • Cortisol
  • Ritanserin
  • Serotonin receptors
  • β-Endorphin
  • β-Lipotropin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Ritanserin, a serotonin-s<sub>2</sub> receptor antagonist, does not prevent 5-hydroxytryptophan-induced β-ep, β-lph and cortisol secretion'. Together they form a unique fingerprint.

Cite this